Combined medicine for treating cancer

CN119055651APending Publication Date: 2024-12-03SICHUAN HONGHE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310642551.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current cancer treatments, particularly chemotherapy drugs, suffer from significant systemic toxicity, side effects, and drug resistance, necessitating the development of more effective and less harmful combination drug formulations.

Method used

A combined drug formulation comprising β-elemene and a second drug, specifically irinotecan, everolimus, or exemestane, in precise molar ratios, to enhance anti-tumor activity and minimize side effects.

Benefits of technology

The combination of β-elemene with irinotecan, everolimus, or exemestane demonstrates synergistic or additive effects in inhibiting tumor cell growth, reducing systemic toxicity, and overcoming drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to a combined medicine for treating cancer, the combined medicine contains beta elemene, the combined medicine is a single compound preparation or a combination of two single preparations, and the combined medicine effectively realizes the synergism of medicines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a combined drug of beta-elemene for treating cancer, and relates to the field of medicine. Background Art

[0002] Cancer is currently a major disease that threatens human health. In my country, approximately 1.8 million patients are diagnosed with the disease each year, and the incidence rate is increasing year by year. Currently, cancer treatment mainly relies on surgery, chemotherapy, and radiotherapy. However, a large number of chemotherapy drugs currently used in clinical practice still have problems such as large systemic toxicity and side effects, drug resistance, and poor selection. In recent years, a large number of clinical and experimental studies have shown that traditional Chinese medicine and combined drug therapy have special effects in the prevention, treatment, and rehabilitation of tumors, and have gradually become the focus of attention.

[0003] β-elemene is the main component of zedoary turmeric oil and citronella oil, and is now widely used to treat cancer. It has been reported that elemene can be used in combination with anti-tumor drugs such as gefitinib and celecoxib to enhance the inhibitory activity of the above substances on tumor cell growth.

[0004] In order to meet the treatment needs of cancer patients as quickly as possible, it is urgent to develop more clinically valuable combination drug formulations and administration methods. Summary of the invention

[0005] The present invention provides a combined drug for treating cancer, the combined drug comprising β-elemene and a second drug, the combined drug being a single compound preparation or a combination of two separate preparations, and the second drug being selected from irinotecan, everolimus and exemestane.

[0006] Further, the second drug is irinotecan, and the molar ratio of irinotecan to β-elemene is less than 1:4, preferably less than 1:7, preferably 1:1000-1:4, preferably 1:1000-1:7, preferably 1:1000-1:28, preferably 1:1000-1:55, preferably 1:1000-1:111, preferably 1:1000-1:444, preferably 1:444-1:4, preferably 1:444-1:7 , preferably 1:444-1:28, preferably 1:444-1:55, preferably 1:444-1:111, preferably 1:111-1:4, preferably 1:111-1:7, preferably 1:111-1:28, preferably 1:111-1:55, preferably 1:55-1:4, preferably 1:55-1:7, preferably 1:55-1:28, preferably 1:28-1:4, preferably 1:28-1:7, preferably 1:7-1:4.

[0007] Furthermore, the molar ratio of irinotecan to β-elemene is 1:1000, 1:444, 1:111, 1:55, 1:14, 1:10, and 1:7.

[0008] Further, the second drug is everolimus, and the molar ratio of everolimus to β-elemene is 1:1000000-1:0.1, preferably 1:1000000-1:0.5, preferably 1:500000-1:0.5, preferably 1:500000-1:100, preferably 1:500000-1:100, preferably 1:500000-1:5000, preferably 1:500000-1:10000, preferably 1:500000-1:20000, preferably 1:500000-1:31250, preferably 1:500000-1:1250 00, preferably 1:500000-1:250000, preferably 1:250000-1:0.5, preferably 1:250000-1:100, preferably 1:250000-1:1000, preferably 1:250000-1:5000, preferably 1:250000-1:10000, preferably 1:250000-1:20000, preferably 1:250000-1:31250, preferably 1:250000-1:125000, preferably 1:125000-1:0.5, preferably 1:125000-1:100, preferably 1:12500 0-1:1000, preferably 1:125000-1:5000, preferably 1:125000-1:10000, preferably 1:125000-1:20000, preferably 1:125000-1:31250, preferably 1:31250-1:0.5, preferably 1:31250-1:100, preferably 1:31250-1:1000, preferably 1:31250-1:5000, preferably 1:31250-1:10000, preferably 1:31250-1:20000, preferably 1:20000-1:0.5, preferably 1:20000-1 :100, preferably 1:20000-1:1000, preferably 1:20000-1:5000, preferably 1:20000-1:10000, preferably 1:10000-1:0.5, preferably 1:10000-1:100, preferably 1:10000-1:100, preferably 1:10000-1:5000, preferably 1:5000-1:0.5, preferably 1:5000-1:100, preferably 1:5000-1:100, preferably 1:1000-1:0.5, preferably 1:1000-1:100, preferably 1:1000-1:0.5.

[0009] Furthermore, the molar ratio of everolimus to β-elemene is 1:0.5, 1:100, 1:1000, 1:5000, 1:10000, 1:20000, 1:25000, 1:31000, 1:31250, 1:40000, 1:50000, 1:60000, 1:125000, 1:250000, 1:300000, 1:400000, and 1:500000.

[0010] Further, the second drug is exemestane, and the molar ratio of exemestane to β-elemene is 1:0.1-1:1000, preferably 1:7-1:1000, preferably 1:7-1:14, preferably 1:7-1:111, preferably 1:7-1:150, preferably 1:14-1:111, preferably 1:14-1:150, preferably 1:14-1:1000, preferably 1:111-1:150, preferably 1:111-1:1000, preferably 1:150-1:1000.

[0011] Furthermore, the molar ratio of exemestane to β-elemene is 1:10000, 1:1000, 1:150, 1:111, 1:14, 1:7, 1:1, and 1:0.1.

[0012] The present invention provides a pharmaceutical composition for treating cancer. The active ingredients of the pharmaceutical composition include beta-elemene and a second drug, and the second drug is selected from irinotecan, everolimus and exemestane.

[0013] Furthermore, the active ingredients of the pharmaceutical composition consist of β-elemene and irinotecan.

[0014] Further, the molar ratio of irinotecan to β-elemene is less than 1:4, preferably less than 1:7, preferably 1:1000-1:4, preferably 1:1000-1:7, preferably 1:1000-1:28, preferably 1:1000-1:55, preferably 1:1000-1:111, preferably 1:1000-1:444, preferably 1:444-1:4, preferably 1:444-1:7, preferably 1:44 4-1:28, preferably 1:444-1:55, preferably 1:444-1:111, preferably 1:111-1:4, preferably 1:111-1:7, preferably 1:111-1:28, preferably 1:111-1:55, preferably 1:55-1:4, preferably 1:55-1:7, preferably 1:55-1:28, preferably 1:28-1:4, preferably 1:28-1:7, preferably 1:7-1:4.

[0015] Furthermore, the molar ratio of irinotecan to β-elemene is 1:1000, 1:444, 1:111, 1:55, 1:14, 1:10, and 1:7.

[0016] Furthermore, the active ingredients of the pharmaceutical composition consist of β-elemene and everolimus.

[0017] Further, the molar ratio of everolimus to β-elemene is 1:1000000-1:0.1, preferably 1:1000000-1:0.5, preferably 1:500000-1:0.5, preferably 1:500000-1:100, preferably 1:500000-1:100, preferably 1:500000-1:5000, preferably 1:500000-1:10000, preferably 1:500000-1:20000, preferably 1:500000-1:31250, preferably 1:500000-1:125000, preferably 1:500 0000-1:250000, preferably 1:250000-1:0.5, preferably 1:250000-1:100, preferably 1:250000-1:1000, preferably 1:250000-1:5000, preferably 1:250000-1:10000, preferably 1:250000-1:20000, preferably 1:250000-1:31250, preferably 1:250000-1:125000, preferably 1:125000-1:0.5, preferably 1:125000-1:100, preferably 1:125000-1:10 00, preferably 1:125000-1:5000, preferably 1:125000-1:10000, preferably 1:125000-1:20000, preferably 1:125000-1:31250, preferably 1:31250-1:0.5, preferably 1:31250-1:100, preferably 1:31250-1:1000, preferably 1:31250-1:5000, preferably 1:31250-1:10000, preferably 1:31250-1:20000, preferably 1:20000-1:0.5, preferably 1:20000-1:10 0, preferably 1:20000-1:1000, preferably 1:20000-1:5000, preferably 1:20000-1:10000, preferably 1:10000-1:0.5, preferably 1:10000-1:100, preferably 1:10000-1:100, preferably 1:10000-1:5000, preferably 1:5000-1:0.5, preferably 1:5000-1:100, preferably 1:5000-1:100, preferably 1:1000-1:0.5, preferably 1:1000-1:100, preferably 1:1000-1:0.5.

[0018] Furthermore, the molar ratio of everolimus to β-elemene is 1:0.5, 1:100, 1:1000, 1:5000, 1:10000, 1:20000, 1:25000, 1:31000, 1:31250, 1:40000, 1:50000, 1:60000, 1:125000, 1:250000, 1:300000, 1:400000, and 1:500000.

[0019] Furthermore, the active ingredients of the pharmaceutical composition consist of β-elemene and exemestane.

[0020] Further, the molar ratio of exemestane to β-elemene is 1:0.1-1:1000, preferably 1:7-1:1000, preferably 1:7-1:14, preferably 1:7-1:111, preferably 1:7-1:150, preferably 1:14-1:111, preferably 1:14-1:150, preferably 1:14-1:1000, preferably 1:111-1:150, preferably 1:111-1:1000, preferably 1:150-1:1000.

[0021] Furthermore, the molar ratio of exemestane to β-elemene is 1:10000, 1:1000, 1:150, 1:111, 1:14, 1:7, 1:1, and 1:0.1.

[0022] Further, the present invention provides a pharmaceutical composition for treating cancer comprising the above-mentioned combined drug, wherein the pharmaceutical composition comprises pharmaceutically acceptable pharmaceutical excipients, including but not limited to injection oil, carrier, filler, disintegrant, binder, lyophilization protectant, pH regulator, preservative, antioxidant, wetting agent, etc. The pharmaceutical composition can be prepared into a preparation, and the preparation can be one or more of tablets, capsules, pills, mixtures, gels, ointments, granules, powders, pastes, granules, pills, oral liquids, drop pills, injections or injections, or any other dosage form.

[0023] Furthermore, the present invention provides a use of the above-mentioned composition or drug in the preparation of a combined drug for treating cancer.

[0024] Furthermore, the cancer is breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), malignant melanoma, colorectal cancer, malignant pleural mesothelioma, pancreatic cancer, head and neck cancer, gastric cell carcinoma, bladder cancer, bone cancer, esophageal cancer, brain tumor, liver cancer, cervical cancer, cancerous chest, ascites, and preferably the cancer is breast cancer or renal cell carcinoma.

[0025] Specific implementation examples

[0026] The technical solution of the present invention is further described in detail below in conjunction with the specific implementation examples of the specification, but the implementation of the present invention is not limited thereto. The equivalent replacement, combination, improvement or modification of the technical solution of the present invention made by those skilled in the art based on the description of the present invention should be included in the protection scope of the present invention.

[0027] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0028] Examples 1-3 were carried out using the following cell culture method:

[0029] Cell culture: Human breast cancer MCF7 was inoculated in a sterile culture bottle, and an appropriate amount of EMEM+2mM Glu+1%NEAA+10%FBS medium was added. The cells were cultured in an incubator at 37°C, 5%CO2 and saturated humidity. The cells grew in a monolayer and were passaged once every 2 to 3 days. During passage, the cells were digested with 0.25% trypsin + 0.02% EDTA for 2 to 4 minutes, and the culture medium was pipetted and blown to make the cells into a cell suspension, and then inoculated according to the required concentration.

[0030] Examples 1-4 use the following calculation method:

[0031] 1) Determination of the effect of dual-drug combination therapy:

[0032] The determination was made using the Jin Zhengjun q value method (see the literature: Dai Tijun. Quantitative analysis of combined medication [J]. Chinese Pharmacological Bulletin, 1998 (5): 479-480.). q = P (A+B) / (P A +P B -P A ×P B ). Where P A , P B and P A+B The inhibition rates are β-elemene group, second drug group and two-drug combination group. q<1 indicates that the two drugs produce antagonism after combination; q>1 indicates that the two drugs produce synergistic effect after combination; q=1 indicates that the two drugs produce additive effect after combination.

[0033] Example 1

[0034] β-elemene and exemestane were divided into: Group 1: 2690uM β-elemene, Group 2: 403.5uM β-elemene, Group 3: 300uM β-elemene, Group 4: 37.5uM β-elemene, Group 5: 18.75uM β-elemene, Group 6: 2.69uM exemestane;

[0035] Group 7: 2690uM β-elemene + 2.69uM exemestane, Group 8: 403.5uM β-elemene + 2.69uM exemestane, Group 9: 300uM β-elemene + 2.69uM exemestane, Group 10: 37.5uM β-elemene + 2.69uM exemestane, Group 11: 18.75uM β-elemene + 2.69uM exemestane.

[0036] The above groups all used 0.5% DMSO as the solvent.

[0037] Methods: Take MCF7 cells in the logarithmic growth phase, make a single cell suspension according to the passaging method, count, and adjust the cell concentration to: 3.34*10^4 cells / mL. The above cell suspension was inoculated in a 96-well cell culture plate, and 90μL of cell suspension was added to each well. The wells without cell culture medium were used as blank zero. After the culture plate was placed in a 37°C, 5% CO2 incubator for 12 hours, 10μL (5μL of different concentrations of β-elemene and 5μL of exemestane) was added to groups 7-11, 5μL of different concentrations of β-elemene + 5μL of 5% DMSO culture medium was added to groups 1-5, 5μL of exemestane + 5μL of 5% DMSO culture medium was added to group 6, and 10μL of 5% DMSO culture medium was added to the vehicle control. Duplicate wells were set for each group, and after 72h of culture, 50μL of CellTiter-Glo was added to each well. TM Reagent, on an oscillator, protected from light, at 300 rpm / min for 3 min, let stand for 10 min, and then use an automatic microplate reader to measure the fluorescence signal value of each well.

[0038] The results are shown in Table 1.

[0039]

[0040] Example 2

[0041] Beta-elemene and irinotecan are divided into:

[0042] Group 1: 300uM elemene, Group 2: 150uM elemene, Group 3: 75uM elemene, Group 4: 18.75uM elemene, Group 5: 10.76uM elemene, Group 6: 2.69uM irinotecan

[0043] Group 7: 300uM elemene + 2.69uM irinotecan, Group 8: 150uM elemene + 2.69uM irinotecan, Group 9: 75uM elemene + 2.69uM irinotecan, Group 10: 18.75uM + 2.69uM irinotecan, Group 11: 10.76uM elemene + 2.69uM irinotecan

[0044] The above groups all used 0.5% DMSO as the solvent.

[0045] Methods: Take MCF7 cells in the logarithmic growth phase, make a single cell suspension according to the passaging method, count, and adjust the cell concentration to: 3.34*10^4 cells / mL. The above cell suspension was inoculated in a 96-well cell culture plate, and 90μL of cell suspension was added to each well. The wells without cell culture medium were taken as blank controls and zeroed. After the culture plate was placed in a 37°C, 5% CO2 incubator for 12 hours, 10μL (5μL of different concentrations of β-elemene and 5μL of irinotecan) was added to groups 7-11, 5μL of different concentrations of β-elemene + 5μL of 5% DMSO culture medium was added to groups 1-5, and 5μL of irinotecan + 5μL of 5% DMSO culture medium was added to group 6. The solvent control was to add 10μL of 5% DMSO culture medium. Each group was set up with duplicate wells, and after 72h of culture, 50μL of CellTiter-Glo was added to each well. TM Reagent, on an oscillator, protected from light, at 300 rpm / min for 3 min, let stand for 10 min, and then use an automatic microplate reader to measure the fluorescence signal value of each well.

[0046] The experimental results are shown in Table 2:

[0047]

[0048]

[0049] Example 3

[0050] Beta-elemene and everolimus are divided into:

[0051] Group 1: 500uM β-elemene, Group 2: 250uM β-elemene, Group 3: 125uM β-elemene, Group 4: 31.25uM β-elemene, Group 5: 20uM β-elemene, Group 6: 1nM everolimus.

[0052] Group 7: 500uM β-elemene + 1nM everolimus, Group 8: 250uM β-elemene + 1nM everolimus, Group 9: 125uM β-elemene + 1nM everolimus, Group 10: 31.25uM β-elemene + 1nM everolimus, Group 11: 20uM β-elemene + 1nM everolimus.

[0053] The above groups all used 0.5% DMSO as the solvent.

[0054] Methods: Take MCF7 cells in the logarithmic growth phase, make a single cell suspension according to the passaging method, count, and adjust the cell concentration to: 3.34*10^4 cells / mL. The above cell suspension was inoculated in a 96-well cell culture plate, and 90μL of cell suspension was added to each well. The wells without cell culture medium were used as blank zero. After the culture plate was placed in a 37℃, 5% CO2 incubator for 12 hours, 10μL (5μL of different concentrations of β-elemene and 5μL of everolimus) was added to groups 7-11, 5μL of different concentrations of β-elemene + 5μL of 5% DMSO culture medium was added to groups 1-5, and 5μL of everolimus + 5μL of 5% DMSO culture medium was added to group 6. The solvent control was to add 10μL of 5% DMSO culture medium. Each group was set up with duplicate wells, and after 72h of culture, 50μL of CellTiter-Glo was added to each well. TM Reagent, on an oscillator, protected from light, at 300 rpm / min for 3 min, let stand for 10 min, and then use an automatic microplate reader to measure the fluorescence signal value of each well.

[0055] The experimental results are shown in Table 3:

[0056]

[0057] Example 4

[0058] Beta-elemene and everolimus are divided into:

[0059] Group 1: 500uM β-elemene, Group 2: 250uM β-elemene, Group 3: 125uM β-elemene, Group 4: 31.25uM β-elemene, Group 5: 20uM β-elemene, Group 6: 10uM β-elemene, Group 7: 5uM β-elemene, Group 8: 1uM β-elemene, Group 9: 0.1uM β-elemene, Group 10: 0.0005uM β-elemene, Group 11: 1nM everolimus;

[0060] Group 12: 500uM uM β-elemene + 1nM everolimus, group 13: 250uM β-elemene + 1nM everolimus, group 14: 125uM β-elemene + 1nM everolimus, group 15: 31.25uM β-elemene + 1nM everolimus, group 16: 20uM β-elemene + 1nM everolimus, group 17: 10uM β-elemene + 1nM everolimus, group 18: 5uM β-elemene + 1nM everolimus, group 19: 1uM β-elemene + 1nM everolimus, group 20: 0.1uM β-elemene + 1nM everolimus, group 21: 0.0005uM β-elemene + 1nM everolimus.

[0061] The above groups all used 0.5% DMSO as the solvent.

[0062] Cell culture method: Cell culture: Human renal cell carcinoma SK-NEP-1 was inoculated into a sterile culture bottle, and an appropriate amount of McCoy's 5a + 15% FBS medium was added, and cultured in an incubator at 37°C, 5% CO2 and saturated humidity. The cells grew in a monolayer and were passaged once every 2 to 3 days. During passage, the cells were digested with 0.25% trypsin + 0.02% EDTA for 2 to 4 minutes, and the culture medium was pipetted and blown to make the cells into a cell suspension, and then inoculated according to the required concentration.

[0063] Methods: SK-NEP-1 cells in the logarithmic growth phase were taken, and single cell suspension was made according to the passaging method, counted, and the cell concentration was adjusted to: 5.56*10^4. The above cell suspension was inoculated in a 96-well cell culture plate, and 90μL of cell suspension was added to each well. The wells without cell culture medium were taken as blank zero. After the culture plate was placed in a 37℃, 5% CO2 incubator for 12 hours, 10μL (5μL of different concentrations of β-elemene and 5μL of everolimus) were added to groups 12-21, 5μL of different concentrations of β-elemene + 5μL of 5% DMSO culture medium were added to groups 1-10, 5μL of everolimus + 5μL of 5% DMSO culture medium was added to group 11, and 10μL of 5% DMSO culture medium was added to the vehicle control group. Each group was set up with duplicate wells, and after 72h of culture, 50μL of CellTiter-Glo was added to each well. TM Reagent, on an oscillator, protected from light, at 300 rpm / min for 3 min, let stand for 10 min, and then use an automatic microplate reader to measure the fluorescence signal value of each well.

[0064] The experimental results are shown in Table 4:

[0065]

[0066]

Claims

1. A combined drug for treating cancer, characterized in that The combination drug comprises β-elemene and a second drug, and the combination drug is a single compound preparation or a combination of two separate preparations. Preferably, the second drug is selected from irinotecan, everolimus, and exemestane.

2. The combined drug according to claim 1, characterized in that The molar ratio of irinotecan to β-elemene is less than 1:4, preferably less than 1:7, preferably 1:444-1:7, preferably 1:111-1:

7.

3. The combined drug according to claim 1, characterized in that The molar ratio of everolimus to β-elemene is 1:1000000-1:0.1, preferably 1:500000-1:0.5, preferably 1:250000-31250, preferably 1:250000-1:125000.

4. The combined drug according to claim 1, characterized in that The molar ratio of exemestane to β-elemene is 1:0.1-1:1000, preferably 1:7-1:1000, preferably 1:7-1:

14.

5. A pharmaceutical composition for treating cancer, characterized in that The active ingredients of the pharmaceutical composition include β-elemene and a second drug, preferably the second drug is selected from irinotecan, everolimus, and exemestane, preferably the active ingredients of the pharmaceutical composition consist of β-elemene and irinotecan, or β-elemene and everolimus, or β-elemene and exemestane, and preferably the pharmaceutical composition contains pharmaceutically acceptable excipients.

6. The pharmaceutical composition according to claim 5, characterized in that The molar ratio of irinotecan to β-elemene is less than 1:4, preferably less than 1:7, preferably 1:444-1:7, preferably 1:111-1:

7.

7. The pharmaceutical composition according to claim 5, characterized in that The molar ratio of everolimus to β-elemene is 1:1000000-1:0.1, preferably 1:500000-1:0.5, preferably 1:250000-31250, preferably 1:250000-1:125000.

8. The combined drug according to claim 5, characterized in that The molar ratio of exemestane to β-elemene is 1:0.1-1:1000, preferably 1:7-1:1000, preferably 1:7-1:

14.

9. Use of the composition or drug according to any one of claims 1 to 8 in the preparation of a combined drug for treating cancer, wherein the cancer is preferably breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), malignant melanoma, colorectal cancer, malignant pleural mesothelioma, pancreatic cancer, head and neck cancer, gastric cell carcinoma, bladder cancer, bone cancer, esophageal cancer, brain tumor, liver cancer, cervical cancer, cancerous chest, ascites, and preferably the cancer is breast cancer or renal cell carcinoma.

Citation Information

Cited By

  • Drug containing elemene and kinase inhibitor

    WO2025149017A1